June 2018

COMPANY PROFILE

INDEX

PRODUCTS

BUSINESS MODEL

GROUP

MARKETM ECONOMIC DATA

MANAGEMENT

FINANCIAL DATA

GROWTH DRIVERS

2

GROUP

3

PHARMANUTRA HOLDS 100% OF JUNIAPHARMA AND ALESCO

100%100%

4

Established 2003

Medical devices and dietary supplements for adults

Established 2010

Medicinal products, medical devices, OTC and dietary supplements for children

Established 2000Development and manufacturing.Unique and exclusive proprietary bioactive ingredients

PRODUCTS

5

MAIN PRODUCTS

Dietary Supplements and Medical Devices for iron

supplementation and joint pain relief

6

WE HAVE THE BEST PRODUCT TO FIGHT ANEMIA – THE BIGGEST WORLD DISEASE

IronDeficiency

AnemiaCancer

GastrointestinalConditions

Women’s Health

Chronic KidneyDisease

Congestive HeartFailure

Low Birth Weight and Premature

Infants

Multiple ChronicParasitic

Infections

7

1.4 billion people suffering EDA in the world.

SIDERAL PRODUCT RANGE

Nutritional supplement based on Sucrosomial Iron

> Innovative technology using Sucrosomial Iron ultradispersed in sucresther.

> Excellent gastrointestinal tolerability> It can be taken also by coeliacs

High concentration Sucrosomial Iron

> To prevent typical iron deficiencies in women> With Folic Acid, Vitamin C, B6, B12 and D3.> Excellent palatability and great taste> One sachet a day, no need to use water

> High bioavailability> Useful for rebalancing haemoglobin levels> High tolerability and compliance

Sucrosomial Iron that dissolves in the mouth

> All the advantages of Sucrosomial Iron with all the benefits of folic acid, vitamin B6 and B12 to maintain cardiac function> Specific formulation for a healthy heart.> Contributes to normal oxygen transport in the body.> Not inferior to intravenous iron

Sucrosomial Iron with Folic Acid for iron deficiencies relating to cardiology

Sucrosomial Iron, vitamin C and B Vitamins. Sideral Bimbi is an

innovative source of high bioavailability iron, found

in iron pyrophosphate liposome complexes.

The first SUCROSOMIAL iron for newborns.

Iron is the mineral present at the highest

concentration in blood and is found in every living

cell

Sucrosomial Iron, vitamin C and B-group vitamins.

Sideral Oro is an innovative source of high bioavailability iron found

in iron pyrophosphate sucrosomes

8

CETILAR PRODUCT RANGE

Topical Cream with 7.5% of cetylated fattyacids (CFA).Medical Device Class 2ACetilar®, a massage coadiuvant, improvesarticulations and brings relief to jointsaffected by osteoarthritis. Massages help easejoint and musculoskeletal pain, which can also be beneficial to sport related injuries.

Cetilar® Patch for joints, muscles and tendons with high concentration of Cetylated Fatty Acids (CFA 7.5%) thatallows pain relief with no side effects

9

BUSINESS MODEL

10

PHARMANUTRA’S UNIQUENESS

ALL OTHERS(DRUGS)

PHARMANUTRA

(NO DRUGS)

COMPANY A• Substance discovery• Efficacy development• Pharmaceutical form

development• Patents

COMPANY B• Marketing• Communication

• Medical Detailing• Sales

WE DO BOTH

TIME TO MARKET

3-8 YEARS

TIME TO MARKET

1-3 YEARS

PURCHASE

TWO COMPANIES IN ONEFROM PURE DISCOVERY TO DIRECT SALE TO CONSUMERS

11

ITALY BUSINESS MODEL

PHARMACIES

OUR ISC - INFORMATION MEDICAL DETAILERS FOR SCIENCE AND COMMERCECOVER THE ENTIRE SUPPLY CHAIN

WHOLESALERS DOCTORS direct orders

Our Scientific and Commercial Information model is officially recognised

We DIRECTLY manage the retail, promotion and sale of all products in our portfolio

We produce UNIQUE and innovative products managing the entire production process, from raw materials to end product

12

INTERNATIONAL BUSINESS MODEL

PharmaNutra operatesin 58 COUNTRIES with 29 PARTNERS, carefully selected among the best international pharmaceutical and nutraceutical companies.

13

CLINICAL EVIDENCES

14

The effectiveness of our products is DEMONSTRATED by means of significant proprietary clinical data

79 PUBLISHED STUDIES

13 ON-GOING CLINICAL TRIALS

ALMOST 6,000 PATIENTS TREATED

RESEARCH&

DEVELOPMENT

PHARMANUTRA IP PROTECTION STRATEGY

7 PATENTSBASED ON PURE

INNOVATION

UNIQUE competitive advantage

on competitors

2

25 BRANDSREGISTERED

UNIQUE DISTINCTIVENESS

and brand awareness in the

medical field

3

79 CLINICALTRIALS

UNIQUEefficacy

results, proven by a relevant amount of clinical evidences

4

8 PROPRIETARY RAW MATERIALS

UNIQUE proprietary

supply chain

1

NONE OF OUR COMPETITORS IN THE DIETARY SUPPLEMENTS AND MEDICAL DEVICES INDUSTRY HAS OUR FOUR STRONG PILLARS

WITHIN A SINGLE COMPANY

15

MARKETM

16

PHARMANUTRA RANKING IN THE NUTRACEUTICAL MARKET IN ITALY

In 2016 Pharmanutra placed itself 16th among the main nutraceutical companies operating in the Italian market, jumping 38 positions in 7 years

2010 2011 2012 2013 2014

5440

3330

2119

16

2015 2016

17

FOOD SUPPLEMENTS IRON MARKET VALUE

51,3 €

58,7 €

64,9 €

40,74% 41,00%41,37%

49,03% 48,94%49,48%

40,00%

41,00%

42,00%

43,00%

44,00%

45,00%

46,00%

47,00%

48,00%

49,00%

50,00%

€ 40

€ 45

€ 50

€ 55

€ 60

€ 65

€ 70

YEAR 2015 YEAR 2016 YEAR 2017

MIO

Food Supplements Iron Market VALUE and % Sideral Market Share - Tot Year

TOT. MARKET (value) SIDERAL % MARKET SHARE (Units) SIDERAL % MARKET SHARE (Value)

18

IRON MARKET IN ITALY

Expected Evolution of total iron market in Italy -Units

Total market – IRON-based 04F2INT. Classes, B03A EMAT. FERR. ASS – Data source: IMS Health

Total market – IRON-based 04F2INT. Classes, B03A EMAT. FERR. ASS – Data source: IMS Health, Ministry of Health and internal estimates

Total Iron Market in Italy 2017 - Units

- PBM (Patient Blood Management)- Other new fields of use

19

5.256.07461%

3.377.14939%

DRUGS FOOD SUPPLEMENTS

6.000.00041%

8.633.22359%

EXISTING NEW MARKETS

ANTI-INFLAMMATORY TOPICAL CREAM MARKET VALUE

€ 280

€ 290

€ 301

0,90%1,07%

1,39%

1,49%

1,71%

2,15%

0,00%

0,50%

1,00%

1,50%

2,00%

2,50%

€ 265

€ 270

€ 275

€ 280

€ 285

€ 290

€ 295

€ 300

€ 305

YEAR 2015 YEAR 2016 YEAR 2017

MIO

Tot. Market VALUE and % Cetilar Market Share - Tot Year

TOT. MARKET (value) CETILAR % MARKET SHARE (Units) CETILAR % MARKET SHARE (Value)

20

TOPICAL ANTI-INFLAMMATORY MARKET IN ITALY – CETILAR TARGET

Total market – classes 02E1 TOPICAL PRODUCTS FOR MUSCULAR PAIN , 02G1 TOPICAL PRODUCTS FOR PRD X JOINTS – Data source: IMS Health

Total market – classes 02E1 TOPICAL PRODUCTS FOR MUSCULAR PAIN , 02G1 TOPICAL PRODUCTS FOR PRD X JOINTS – Data source: IMS Health and internal estimates

* RETAIL PRICE VALUE

% Cetilar Total Italian Market share 2017 - Value % Cetilar Target Market share 2019 - Value

Market Value*€ 301 Million

21

ECONOMIC DATA

22

TURNOVER AND EBITDA GROWTH BY COMPANY

23

TURNOVER BREAKDOWN BY GEOGRAPHY

24

ITALY ROW

SALES UNITS BREAKDOWN BY GEOGRAPHY

25

FINANCIAL DATA

26

2017 – FINANCIAL RESULTS

27

2017 - NET FINANCIAL POSITION

28

DIVIDEND PAY-OUT

29

Dividend pay-out policy 50% of Group Net

Income

MARKET CAP

30

July – 17 listing June – 18 listing

+ 56%

139 €

SHAREHOLDERS STRUCTURE

Historical PHN Shareholders

*of which Ipo Club 5,1%

31

IPOC 1 S.r.l.

SHARE PRICE PERFORMANCE

Share price atJune, 2914,4 €

32

MANAGEMENT

33

CORPORATE MANAGEMENT

We believe in team work, and our team is keen and enthusiastic.We are directly involved in the growth of the Group and its people

Andrea Lacorte | President Roberto Lacorte | CEO & Vice President

The group’s founder has scientific training, is involved in devising the products’ pharmaceutical forms and is the undisputed reference point for the sales network. Practical, ambitious and responsible, he leads the company without ever holding back.

Chartered accountant, keen sportsman, engaged and attentive, he brings determination, discipline and enthusiasm to the group, qualities that move every great company to achieve success. Visionary and dreamer, an important pillar for the entire team.

Carlo Volpi | Chief Operating Officer

With a solid training in the international arena and consultancy firms, in addition to important experiences in multinational pharmaceutical companies, he strongly believed in Pharmanutra’s potential, devoting himself daily to its growth.

34

BOARD OF DIRECTORS

CHAIRMANR&D & Sales

CEO - Finance, legal,

administration, comunication

CSOChief Scientific

Officer

COOChief Operating

Officier

FINANCE

HRRecruiter

COMMERCIAL DIRECTOR

Export Manager

ALESCOHead of

International Back Office

Controlling, Business

Intelligence & SFE

DIRECTORProduction &

Logistics

CSOScience, R&D,

Quality

IT MANAGER

TECHNICAL ASSISTANT

ALESCOSenior

OperationOfficer

IT Manager

Comunication& EventManager

Calabughis.r.l.

OUTSOURCING

ORGANIZATIONAL STRUCTURE

SALES MANAGER

AREA MANAGER

Sales Rep

AREA MANAGER

Sales Rep

Junia PharmaSales Manager

Head of Marketing & Comunication

Graphic Manager

35

GROWTH DRIVERS

36

ITALY GROWTH DRIVERS

We are reinforcing our sales network.Increasing Scientific Sales Reps from 130 to 200.

We have now a better coverageto actively promote a range of products which is continuouslygrowing.

200SSR

170 SALES REPSON THE FIELD TODAY

130SSR

2017

BY JANUARY 2019

37

CROSS-CHANNEL COMMUNICATION PLAN

MARKETING MATERIAL

COMMERCIAL

DATA BASEBUILDING

SEARCH

SOCIAL MEDIA & CONTENT

PHARMACYSPORTEVENTS

APP

THE USER IS CENTRAL

38

7 NEW PRODUCTS LAUNCH IN 2018

Foreign Market

JANUARY SEPTEMBERAPRIL

2 New SideralProducts

2 New CetilarProducts

30

2 New Productsin supportive care

39

INTERNATIONAL GROWTH DRIVERS

l PRODUCT PORTFOLIO EXPANSION among existing partners

l OPENING OF NEW MARKETS

l CREATION OF SUBSIDIARIES in selected countries

5 NEW CONTRACTS

Vietnam (+ FRR: Laos, Cambogia, Burma), Malaysia (+ FRR: Singapore),

South Africa / Namibia; Egypt, Poland.

There are now 6 new negotiations open and ongoing with additional

countries.

40

SCIENTIFIC RESEARCH ACTIVITIES

Collaborations

Basic Research• Full paper study on Sucrosomial Iron absorption

(European Journal of Pharmacological Science)• 2 posters presented at the ASH Atlanta• 1 Poster presented at the International Bioiron Society, UCLA, US• 2 Posters presented at the EIC, European Iron Club• Full paper study on Ultramag bioavailability

(in collaboration with the University of Pisa and a US Clinic)

Clinical Research• Full paper study about celiac disease conducted at Coeliac Center at Milan Polyclininc• Full paper study on Cetilar treatment in subjects with knee osteoarthritis conducted at Parma

Main Hospital• Agreement with Contract Research Organization – Switzerland for an international randomized

multicentric (1 center in USA, 1 in Italy and 3 in other European countries) clinical study on womenwith post-partum anemia.

SucrosomialIron has beendescribed as a real innovatonby 3 different

ConsensusPaper

41

NEW R&D CENTRE & MANUFACTURING

42

43

43